Clinical Trial Update: A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris [Phase 1]

View source ↗

Summary

A Phase 1 trial update reports completion of a bioavailability study comparing tazarotene 0.1% foam and tazarotene 0.1% gel in subjects with acne vulgaris. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• Tazarotene Foam 0.1% (tazarotene)
• Tazorac Gel 0.1% (tazarotene 0.1% gel)

Snippet

Sponsor: Stiefel, a GSK Company | Conditions: Acne Vulgaris | Phase 1 | Status: COMPLETED